Modulation of autoimmune disease in the MRL-lpr/lpr mouse by IL-2 and TGF-β1 gene therapy using attenuated Salmonella typhimurium as gene carrier

Lupus

Volumn 8, Issue 1, 1999, Pages 29-38

  Huggins, M L ^a,b   Huang, F P ^a   Xu, D ^a   Lindop, G ^a   Stott, D I ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Gene therapy; IL 2; MRL lpr lpr; Salmonella typhimurium; SLE; TGF

Indexed keywords

AUTOANTIBODY; CELL NUCLEUS ANTIGEN; CYTOKINE; INTERLEUKIN 2; MITOGENIC AGENT; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; EXPRESSION VECTOR; FEMALE; GENE THERAPY; GLOMERULONEPHRITIS; LYMPHATIC SYSTEM TUMOR; LYMPHOCYTE PROLIFERATION; MODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SALMONELLA TYPHIMURIUM; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; VASCULITIS;

ANIMALS; ANTIBODIES, ANTINUCLEAR; FEMALE; GENE THERAPY; INTERLEUKIN-2; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED MRL LPR; SALMONELLA TYPHIMURIUM; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR BETA;

EID: 0033046191     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120399678847308     Document Type: Article

References (37)

1. Hahn BH. Antibodies to DNA. New Engl J. Med. 1998; 338; 1359-1367.
2. Watanabe-Fukunaga R et al. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356: 314-317.
3. Izui S et al. Induction of various autoantibodies by mutant gene lpr in several strains of mice. J Immunol 1984; 133: 227-233.
4. Mysler E et al. The apoptosis-1/Fas protein in human systemic lupus erythematosus. J Clin, Invest. 1994 93: 1029-1034.
5. Ohsaka S et al. Expression and function of Fas antigen and Bcl-2 in human systemic lupus erythematosus lymphocytes. Clin Immunol Immunopathol 1994; 73: 109-114.
6. Handwerger BS, Rus V, Da SL, Via CS. The role of cytokines in the immunopathogenesis of lupus. Springer Seminars in Immunopathology 1994; 16: 153-180.
7. Horwitz DA, Jacob CO. The cytokine network in the pathogenesis of systemic lupus erythematosus and possible therapeutic implications. Springer Seminars in Immunopathology 1994; 16: 181-200.
8. Kroemer G, Wick G. The role of interleukin-2 in autoimmunity. Immunol Today 1989; 10: 246-251.
9. Murakawa Y et al. Characterization of T lymphocyte subpopulations responsible for deficient IL-2 activity in patients with systemic lupus erythematosus. J Immunol 1985; 134: 187-194.
10. Huang F-P, Stott DI. Restoration of an early, progressive defect in responsiveness to T-cell activation in lupus mice by exogenous IL-2. Autoimmunity 1993; 15: 19-29.
11. + T cells. Eur J Immunol 1995; 25: 3053-3059.
12. Horak I, Lohler J, Ma A, Smith KA. Interleukin-2 deficient mice: A new model to study autoimmunity and self-tolerance. Immunological Reviews 1995; 148: 35-44.
13. Wahl SM et al. Transforming growth factor-β is a potent immuno-suppressive agent that inhibits IL-1-dependent lymphocyte proliferation. J Immunol 1988 140: 3026-3032.
14. Kuruvilla AP et al. Protective effect of transforming growth factor beta 1 on experimental autoimmune diseases in mice. Proc Natl Acad Sci USA 1991; 88: 2918-2921.
15. Lotze MT et al. In vivo administration of purified human interleukin-2. I. Half-life and immunologic effects of the Jurkat cell line-derived IL-2. J Immunol 1985; 134: 157-166.
16. Wakefield LM et al. Recombinant latent transforming growth factor β1 has a longer plasma half-life in rats than active transforming growth factor β1, and a different tissue distribution. J Clin Invest 1991; 86: 1976-1984.
17. Charles IG, Dougan G. Gene expression and the development of live enteric vaccines. TIBTECH 1990; 8: 117-121.
18. - Salmonella typhimurium expressing cloned streptococcal M protein. J Exp Med 1988; 168: 25-32.
19. Sadoff JC et al. Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria. Science 1988; 240: 336-338.
20. -) vaccine expressing a major leishmanial surface protein (gp63) preferentially induced Th1 cells and protective immunity against leishmaniasis. J Immunol 1990; 145: 2281-2285.
21. Carrier MJ et al. Expression of human IL-1β in Salmonella typhimurium. A model system for the delivery of recombinant therapeutic proteins in vivo. J Immunol 1992; 148: 1176-1181.
22. Darji A et al. Oral somatic transgene vaccination using attenuated Salmonella typhi. Cell 1997; 91: 765-775.
23. Xu D et al. Protective effect on Leishmania major infection of migration inhibitory factor, TNF-α, and IFN-γ administered orally via attenuated Salmonella typhimurium. J Immunol 1998; 160: 1285-1289.
24. Denich K et al. Expression of the murine interleukin-4 gene in an attenuated aroA strain of Salmonella typhimurium: persistence and immune response in BALB/c mice and susceptibility to macrophage killing. Inject Immun 1993; 61: 4818-4827.
25. Ianaro A et al. Expression of IGF-β in attenuated Salmonella typhimurium: oral administration leads to the reduction of inflammation, IL-2 and IFN-γ, but enhancement of IL-10, in carrageenin-induced oedema in mice. Immunology 1995; 84: 8-15.
26. Gillis S et al. T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol 1978; 120: 2027-2032.
27. Huang F-P, Stott DI. Dual inhibitory and stimulatory activities in serum from SLE patients and lupus mice that regulate the proliferation of an IL-2-dependent T cell line. Lupus 1995; 4: 297-303.
28. Like B, Massague J. The antiproliferative effect of type β transforming growth factor occurs at a level distal from receptors for growth-activating factor. J Biol Chem 1986; 261: 13426-13429.
29. Stott DI, Brighouse G, Gyotoku Y, Lambert P-H. Analysis of the autoimmune response in lupus mice: The behaviour and lifespan of anti-DNA-secreting B-cell clones. Autoimmunity 1990; 8: 159-168.
30. Gutierrez-Ramos JC et al. Recovery from autoimmunity of MRL/lpr-mice after infection with an interleukin-2/vaccinia recombinant virus. Nature 1990; 346: 271-274.
31. Lowrance JH et al. Spontaneous elaboration of transforming growth factor β suppresses host defense against bacterial infection in autoimmune MRL/lpr mice. J Exp Med 1994; 180: 1693-1703.
32. Huang Y-P et al. Correlation of T and B cell activities in vitro and serum IL-2 levels in systemic lupus erythematosus. J Immunol 1988; 141: 827-833.
33. Theze J, Alzari PM, Bertoglio J. Interleukin 2 and its receptors: recent advances and new immunological functions. Immunol Today 1996; 17: 481-486.
34. + T cells are responsible for murine interleukin-2-deficient colitis. Eur J Immunol 1995; 25: 2618-2625.
35. Taguchi O, Takahashi T. Administration of anti-interleukin 2 receptor-α antibody in vivo induces localised autoimmune disease. Eur J Immunol 1996; 26: 1609-1612.
36. Raz E et al. Modulation of disease activity in murine systemic erythematosus by cytokine gene delivery. Lupus 1995; 4: 286-292.
37. Mathisen PM, Tuohy VK. Gene therapy in the treatment of autoimmune disease. Immunol Today 1998; 19: 103-105.